
Sign up to save your podcasts
Or
Moderator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.
Moderator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.
134 Listeners
288 Listeners
27 Listeners
316 Listeners
10 Listeners
47 Listeners
498 Listeners
13 Listeners
22 Listeners
131 Listeners
9 Listeners
10 Listeners
6 Listeners
8 Listeners
78 Listeners